Aridis Pharmaceuticals

05/24/2022

Please reserve your seat for the Fireside Chat with Vu L. Truong, Ph.D. Founder, CEO and Director, and Jason McCarthy, Research Analyst at Maxim Group, on June 7 at 11 AM Eastern.
https://m-vest.com/events/fireside-chat-ards-06072022

02/17/2022

We would like to announce that our pan-coronavirus monoclonal antibody cocktail AR-701 is protective in COVID-19 Omicron infected animals. You can read the full release details here: https://finance.yahoo.com/news/aridis-pan-coronavirus-monoclonal-antibody-114500471.html

: ARDS

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that both of its fully human monoclonal antibodies (mAbs) in the AR-701 cocktail neutralized the S...

02/04/2022

COVID has brought antimicrobials – specifically, the antibodies our bodies use to fight COVID – back into the spotlight, and we're doubling down on the potential by innovating a new antimicrobial treatment that may prove to be as effective as a vaccine in preventing COVID infections and serious symptoms.

“Antimicrobials really aren’t getting the love lately,” said Dr. Vu Truong, CEO of Aridis Pharmaceuticals (Nasdaq: ARDS) as he reviewed the latest data on his own company’s antimicrobial...

01/27/2022

In addition to our Gates Foundation grant award news, we will be hosting a conference call today at 4:15 PM Eastern. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-9208 (U.S. Toll-Free) or 1-201-493-6784 (International) a few minutes before the 4:15 p.m. ET start time. An audio-only webcast is also available by visiting:

01/27/2022

We are proud to say we've received a grant award from the Bill & Melinda Gates Foundation to evaluate the application of our inhaled formulation technology to deliver cost-effective monoclonal antibodies (mAbs) against influenza and SARS-CoV2 to people in low- and middle-income countries. Learn more here:

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, received a grant award from the Bill & Melinda Gates Foundation ('Gates Foundation') to evaluate the application o...

01/07/2022

It's been an time here at Aridis, and we want to make sure you didn't miss it. Our CEO Vu Truong recently discussed our Monoclonal Antibody Cocktail Protection against the COVID-19 Variant and other viruses in an Fox Business Interview. Learn more and watch the full interview here:

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that Vu Truong, Ph.D., Chief Executive Officer, was interviewed on Varney & Co., hosted by Stuart....

01/07/2022

We are happy to H.C. Wainwright is on our -19 Antibody Cocktail. Additionally, H.C. Wainwright analyst Vernon Bernardino reiterated a rating and $19 price target on ARDS shares. Learn more:

By Sam Boughedda